natgillin/translations-raw huggingface dataset:
Zalasta tilhører en gruppe af lægemidler, der kaldes antipsykotika.
Zalasta belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Yderligere information om Zalasta findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Lavsubstitueret hydroxypropylcellulose
Low-substituted hydroxypropylcellulose Aspartame
Patienter med vægtøgning på  7 %,  15 % og ≥25 % af baseline kropsvægt ved langvarig eksponering (mindst 48 uger) var meget almindelig (henholdsvis 64,4 %, 31,7 % og
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tryk forsigtigt tabletten ud i din hånd.
Tip the tablet out onto your hand.
Akutte symptomer såsom perspiration, søvnløshed, rysten, angst, kvalme eller opkastning er rapporteret sjældent (≥ 0,01 % og < 0,1 %) når olanzapin stoppes pludseligt.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ≥ 0.01% and < 0.1%) when olanzapine is stopped abruptly.
- Yderst sjældent forårsager denne slags medicin en kombination af feber, hurtigere vejrtrækning, svedtendens, muskelstivhed og døsighed/søvnighed.
─ Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.
Metabolisme og ernæring Vægtstigning
Metabolism and nutrition disorders Weight gain
Lægemiddelfrem kaldt reaktion med eosinofili og systemiske symptomer (DRESS)
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Ikke anvendte lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer.
Any unused product or waste material should be disposed of in accordance with local requirements.
Det er vist, at Zalasta forebygger tilbagefald af disse symptomer hos patienter med bipolar lidelse (maniodepressiv sygdom), hvis maniske episode har reageret på olanzapinbehandling.
Zalasta has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Hvordan du tager Zalasta
How to take Zalasta
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
Terapeutisk monitorering af valproat-plasmaniveauer indikerer ikke, at en justering af valproat-dosis er nødvendig, når olanzapin gives sammen med valproat.
Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
- Højt sukker- og fedtindhold (triglycerider og kolesterol) i blodet er set hos patienter, som tager Zalasta.
─ High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Zalasta.
Observerede normalniveauer ved faste ved baseline (< 1,016 mmol/l, som steg til (≥ 1,467 mmol/l) og ændringer i triglycerider ved faste fra grænser ved baseline (≥ 1,016 mmol/l-< 1,467 mmol/l) op til (≥ 1,467 mmol/l).
Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l-< 1.467 mmol/l) to high (≥ 1.467 mmol/l).
Der var flere rygere blandt forsøgspersoner med cirrose (4/6; 67 %) end blandt forsøgspersoner uden nedsat leverfunktion (0/3;
There were more smokers among subjects with cirrhosis (4/6; 67 %) than among subjects with no hepatic dysfunction (0/3;
Fluvoxamin, en specifik CYP1A2 inhibitor, er vist signifikant at hæmme metaboliseringen af olanzapin.
Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
- Øvrige indholdstoffer: Mannitol, microkrystallinsk cellulose, crospovidon, lavsubstitueret hydroxypropylcellulose, aspartam, calciumsilicat, magnesiumstearat.
- The other ingredients are mannitol, microcrystalline cellulose, crospovidone, low-substituted hydroxypropylcellulose, aspartame, calcium silicate, magnesium stearate.
Forsigtighed bør udvises hos patienter med lavt leukocyt- og/eller neutrofiltal uanset årsag, hos patienter, som får medicin, der er kendt for at medføre neutropeni, hos patienter med tidligere medicin-induceret knoglemarvsdepression, hos patienter med knoglemarvsdepression forårsaget af samtidig sygdom, strålebehandling eller kemoterapi og hos patienter med hypereosinofile tilstande eller myeloproliferativ sygdom.
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of druginduced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Brug af anden medicin sammen med Zalasta
Other medicines and Zalasta
Zalasta indeholder det aktive stof olanzapin.
Zalasta contains the active substance olanzapine.
Desuden afslørerede et Single Photon
In addition, a Single
Det skal du vide, før du begynder at tage Zalasta
What you need to know before you take Zalasta
Tabletten vil blive opløst med det samme i munden, så du let kan synke den med eller uden vand.
The tablet begins breaking up in the mouth within seconds and can then be swallowed with or without water.
Se punkt 2 ”Zalasta indeholder lactose”
See section 2 "Zalasta contains lactose".
Hvis du stopper pludseligt med at tage Zalasta kan der opstå symptomer så som: svedeture, søvnløshed, tremor, angst, kvalme og opkastninger.
If you suddenly stop taking Zalasta, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
I de fleste af disse tilfælde var tidligere krampeanfald eller risikofaktorer for krampeanfald observeret.
In most of these cases, a history of seizures or risk factors for seizures was reported.
Olanzapin udviste større affinitet til serotonin 5-HT2 end til dopamin D2-receptorerne i in vitro studier og større 5-HT2- end D2-aktivitet i in vivo modeller.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5 HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo, models.
Interaktioner, der potentielt kan påvirke olanzapin Da olanzapin metaboliseres af CYP1A2, kan substanser, som specifikt inducerer eller inhiberer dette isoenzym, påvirke farmakokinetikken af olanzapin.
Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.
Desuden afslørerede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidonresponderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Vurderet ud fra målte værdier fra kliniske studier i Den Integrerede Olanzapindatabase.
As assessed by measured values from clinical trials in the Olanzapine Integrated Database.
Efter kortvarig behandling (gennemsnitlig varighed 47 dage), var vægtøgning  7 % af baseline kropsvægt meget almindelig (22,2 %),  15 % var almindelig (4,2 %) og ≥ 25 % var ikke almindelig (0,8 %).
Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %).
Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥25 % var almindelig (2,5 %).
Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
Hos patienter med nedsat nyrefunktion (kreatinin clearance < 10 ml/min) versus raske forsøgspersoner fandtes ingen signifikant forskel i den gennemsnitlige eliminationshalveringstid (37,7 versus 32,4 timer) eller clearance (21,2 versus 25,0 l/time).
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
Zalasta indeholder - Aktivt stof: Olanzapin.
What Zalasta contains - The active substance is olanzapine.
Forbigående, asymptomatisk forhøjede leveraminotransfe raser (ALAT, ASAT), særlig initialt i behandlingen (se pkt.
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section
Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidonresponderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Hvis du lider af en af de følgende sygdomme, skal du fortælle det til din læge hurtigst muligt: - Slagtilfælde eller forbigående symptomer på slagtilfælde - Parkinsons sygdom - Problemer med prostata (blærehalskirtlen) - Tarmslyng (paralytisk ileus) - Lever- eller nyresygdom - Blodsygdomme - Hjertesygdom - Sukkersyge (diabetes mellitus) - Krampeanfald
If you suffer from any of the following illnesses tell your doctor as soon as possible: ─ Stroke or “mini” stroke (temporary symptoms of stroke) ─ Parkinson's disease ─ Prostate problems ─ A blocked intestine (Paralytic ileus) ─ Liver or kidney disease ─ Blood disorders ─ Heart disease ─ Diabetes ─ Seizures ─ If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)
Almindelig: Forhøjede kolesterolniveauer Nervesystemet
Common: Elevated cholesterol levels
Der anvendes samme dosis og dosisinterval som for olanzapin tabletter.
It has the same dosage and frequency of administration as olanzapine tablets.
Stammen Restless legssyndrom
Restless legs syndrome
Fortæl altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
- Øvrige indholdstoffer: lactosemonohydrat, cellulose, prægelatineret majsstivelse, majsstivelse, kolloid vandfri silica, magnesiumstearat.
- The other ingredients are lactose monohydrate, powdered cellulose, pregelatinised maize starch, maize starch, colloidal anhydrous silica, magnesium stearate.
Zalasta 10 mg tabletter Hver tablet indeholder 161,8 mg lactose.
Zalasta 10 mg tablets Each tablet contains 161.8 mg lactose.
Zalasta smeltetabletter er tilgængelige i æske med 14, 28, 35, 56 eller 70 smeltetabletter i blister (AI/OPA/AI/PVC).
Zalasta orodispersible tablets are available in boxes of 14, 28, 35, 56 or 70 tablets in blisters (Alu/OPA/Alu/PVC).
• blodpropper i venerne (en ikke almindelig bivirkning, som kan forekomme hos op til 1 ud af 100 patienter), særligt i benene (symptomerne omfatter hævelse og smerte i benet samt hudrødme).
• blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
Hvis du har glemt at tage Zalasta Tag dine tabletter lige så snart, du kommer i tanke om det. Du må ikke tage to doser på en dag.
If you forget to take Zalasta Take your tablets as soon as you remember.
Forhøjet alkalisk fosfatase Høje niveauer af kreatinkinase Høje niveauer af gammaglutamyltransferase Høje niveauer af urinsyre
Increased alkaline phosphatase High creatine phosphokinase High Gamma Glutamyltransferase High uric acid
Ventrikulær takykardi/ ventrikel-flimren, pludselig død (se pkt.
Ventricular tachycardia/fibrillat ion, sudden death (see section 4.4)
Bivirkning identificeret fra kliniske studier i Den Integrerede Olanzapindatabase.
Adverse event identified from clinical trials in the Olanzapine Integrated Database.
14 tabletter 28 tabletter 35 tabletter 56 tabletter 70 tabletter
14 tablets 28 tablets 35 tablets 56 tablets 70 tablets
Se punkt 2 ”Olanzapin Krka indeholder aspartam”
See section 2 "Zalasta contains aspartame".
Alternativt kan den dispergeres i et helt glas vand eller anden egnet væske (appelsinjuice, æblejuice, mælk eller kaffe) umiddelbart før administration.
Alternatively, it may be dispersed in a full glass of water immediately before administration.
Hver smeltetablet indeholder enten 5 mg, 7,5 mg, 10 mg, 15 mg eller 20 mg olanzapin.
Each orodispersible tablet contains 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine.
Hver Zalasta tablet indeholder enten 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg eller 20 mg olanzapin.
Each tablet contains 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine.
Du kan komme til at føle dig døsig, hvis Zalasta tages sammen med medicin mod depressioner eller medicin til behandling af angst eller søvnløshed (sovepiller).
Only take other medicines while you are on Zalasta if your doctor tells you that you can. You might feel drowsy if Zalasta is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
7 tabletter 14 tabletter 28 tabletter 35 tabletter 56 tabletter 70 tabletter
7 tablets 14 tablets 28 tablets 35 tablets 56 tablets 70 tablets
Zalasta 5 mg tabletter Hver tablet indeholder 80,9 mg lactose.
Zalasta 5 mg tablets Each tablet contains 80.9 mg lactose.
Zalasta 7,5 mg tabletter Hver tablet indeholder 121,3 mg lactose.
Zalasta 7.5 mg tablets Each tablet contains 121.3 mg lactose.
Hos raske ældre ( 65 år) versus ikke-ældre forsøgspersoner var den gennemsnitlige eliminations halveringstid forlænget (51,8 versus 33,8 timer) og clearance var reduceret (17,5 versus 18,2 l/time).
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr).
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien KRKA-POLSKA Sp. z o.o., ul.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia KRKA-POLSKA Sp. z o.o., ul.
Zalasta 15 mg tabletter Hver tablet indeholder 242,7 mg lactose.
Zalasta 15 mg tablets Each tablet contains 242.7 mg lactose.
Olanzapin viste sig ikke ringere end lithium på det primære slutpunkt for bipolære tilbagefald (olanzapin 30,0 %, lithium 38,3 %; p=0,055).
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p=0.055).
Inden du påbegynder behandling med Zalasta samt jævnligt i løbet af behandlingen skal din læge tage blodprøver for at kontrollere indholdet af sukker og fedt i dit blod.
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Zalasta and regularly during treatment.
Observeret for fastende normalt niveau ved baseline (< 1,69 mmol/l), der blev øget til højt niveau ( 2,26 mmol/l).
Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26 mmol/l).
Ændringer i de totale kolesterolniveauer ved faste fra normale ved baseline (< 4,39 mmol/l) op til (≥ 5,17 mmol/l) blev observeret almindeligt.
Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
Zalasta 2,5 mg tabletter Hver tablet indeholder 40,4 mg lactose.
Zalasta 2.5 mg tablets Each tablet contains 40.4 mg lactose.
Sjældne bivirkninger (forekommer hos op til 1 ud af 1.000 patienter) omfatter ; nedsat kropstemperatur; unormal hjerterytme; pludselig uforklarlig død; betændelse i bugspytkirtlen, som forårsager voldsomme mavesmerter, feber og utilpashed; leversygdom, som viser sig ved gulfarvning af huden og af det hvide i øjnene; muskelsygdom, som viser sig med uforklarlige smerter; forlænget og/eller pinefuld erektion.
Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.
Ændring i fastende triglyceridniveau fra let forhøjet niveau ved baseline ( 1,69-< 2,26 mmol/l) til højt niveau ( 2,26 mmol/l) var meget almindeligt.
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l-< 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Dette lægemiddel indeholder 0,75 mg aspartam pr. 7,5 mg smeltetablet.
This medicine contains 0.75 mg aspartame in each 7.5 mg orodispersible tablet.
Zalasta 20 mg tabletter
Zalasta 20 mg tablets
QTc-forlængelse blev defineret som Fridericia korrigeret QT (QTcF) 500 millisekunder (msek) på et hvilket som helst tidspunkt post-baseline hos patienter med baseline QTcF <500 msek.
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF< 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
- Anvendelse af Zalasta frarådes til ældre, demente patienter, da det kan have alvorlige bivirkninger.
─ The use of Zalasta in elderly patients with dementia is not recommended as it may have serious side effects ─ Medicines of this type may cause unusual movements mainly of the face or tongue.
Spørg lægen eller på apotekspersonalet, hvis der er noget, du er i tvivl om eller føler dig usikker på.
Check with your doctor or pharmacists if you are not sure.
Observeret for fastende normalt niveau ved baseline (< 5,56 mmol/l), der blev øget til højt niveau ( 7 mmol/l).
Observed for fasting normal levels at baseline (< 5.56 mmol/l) which increased to high (≥ 7 mmol/l).
Zalasta 20 mg tabletter EU/1/07/415/027-031
Zalasta 20 mg tablets EU/1/07/415/027-031
Zalasta smeltetabletter 5 mg, 7,5 mg, 10 mg, 15 mg eller 20 mg er gule, runde, let bikonvekse, marmorerede tabletter med mulighed for individuelle pletter.
What Zalasta looks like and contents of the pack Zalasta 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg orodispersible tablets are: round, slightly biconvex, yellow marbled tablets with possible individual spots.
Observeret for fastende normalt niveau ved baseline (< 5,17 mmol/l), der blev øget til højt niveau ( 6,2 mmol/l).
Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2 mmol/l).
Ændring i fastende glucoseniveau fra let forhøjet niveau ved baseline ( 5,56-< 7 mmol/l) til højt niveau ( 7 mmol/l) var meget almindeligt.
Changes in fasting glucose from borderline at baseline (≥ 5.56-< 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Dette lægemiddel indeholder 2,00 mg aspartam pr. 20 mg smeltetablet.
This medicine contains 2.00 mg aspartame in each 20 mg orodispersible tablet.
Zalasta 7,5 mg tabletter
Zalasta 7.5 mg tablets
Almindelige bivirkninger (forekommer hos op til 1 ud af 10 patienter) omfatter ændringer i mængden af visse blodceller, cirkulerende fedtstoffer i blodet samt forbigående forhøjede leverenzymer tidligt i behandlingen; forhøjet sukker i blodet og urinen; forhøjet urinsyre og kreatinkinase i blodet; øget sultfornemmelse; svimmelhed; rastløshed; rysten; unormale bevægelser (dyskinesi); forstoppelse; mundtørhed; hududslæt; tab af styrke; udpræget træthed; væskeophobning, som medfører hævede hænder, ankler eller fødder; feber; ledsmerter og seksuelle problemer såsom nedsat sexlyst (libido) hos mænd og kvinder eller rejsningsbesvær hos mænd.
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Ændring i total fastende kolesterolniveau fra let forhøjet niveau ved baseline ( 5,17-< 6,2 mmol/l) til højt niveau ( 6,2 mmol/l) var meget almindeligt.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17-< 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Zalasta 7,5 mg smeltetablet Hver smeltetablet indeholder 0,75 mg aspartame.
Zalasta 7.5 mg orodispersible tablets Each orodispersible tablet contains 0.75 mg aspartame.
Dette lægemiddel indeholder 1,50 mg aspartam pr. 15 mg smeltetablet.
This medicine contains 1.50 mg aspartame in each 15 mg orodispersible tablet.
Zalasta 2,5 mg tabletter
Zalasta 2.5 mg tablets
Zalasta 15 mg tabletter EU/1/07/415/022-026
Zalasta 15 mg tablets EU/1/07/415/022-026
Zalasta 5 mg tabletter EU/1/07/415/006-010
Zalasta 5 mg tablets EU/1/07/415/006-010
Zalasta 20 mg tabletter Hver tablet indeholder 20 mg olanzapin.
Zalasta 20 mg tablets Each tablet contains 20 mg olanzapine.
Zalasta 7,5 mg tabletter EU/1/07/415/011-015
Zalasta 7.5 mg tablets EU/1/07/415/011-015
Dette lægemiddel indeholder 1,00 mg aspartam pr. 10 mg smeltetablet.
This medicine contains 1.00 mg aspartame in each 10 mg orodispersible tablet.
Zalasta 10 mg smeltetablet Hver smeltetablet indeholder 1,00 mg aspartame.
Zalasta 10 mg orodispersible tablets Each orodispersible tablet contains 1.00 mg aspartame.
Zalasta 15 mg smeltetablet Hver smeltetablet indeholder 1,50 mg aspartame.
Zalasta 15 mg orodispersible tablets Each orodispersible tablet contains 1.50 mg aspartame.
Ændringer i de totale kolesterolniveauer ved faste fra grænser ved baseline (≥ 4,39-< 5,17 mmol/l) op til (≥ 5,17 mmol/l) var meget almindeligt.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39-< 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Zalasta 7,5 mg tabletter Hver tablet indeholder 7,5 mg olanzapin.
Zalasta 7.5 mg tablets Each tablet contains 7.5 mg olanzapine.
Zalasta 10 mg tabletter
Zalasta 10 mg tablets
Zalasta 15 mg tabletter
Zalasta 15 mg tablets
Zalasta 7,5 mg tabletter olanzapin
Zalasta 7.5 mg tablets Olanzapine
Zalasta 5 mg smeltetablet Hver smeltetablet indeholder 0,50 mg aspartame.
Zalasta 5 mg orodispersible tablets Each orodispersible tablet contains 0.50 mg aspartame.
Zalasta 5 mg tabletter
Zalasta 5 mg tablets
Zalasta 20 mg smeltetablet Hver smeltetablet indeholder 2,00 mg aspartame.
Zalasta 20 mg orodispersible tablets Each orodispersible tablet contains 2.00 mg aspartame.
Hvis du har taget for mange Zalasta
If you take more Zalasta than you should
Zalasta 10 mg tabletter Hver tablet indeholder 10 mg olanzapin.
Zalasta 10 mg tablets Each tablet contains 10 mg olanzapine.